Pharmaxis is targeting the following inflammatory and fibrotic diseases using its amine oxidase platform:
- Non-alcoholic steatohepatitis (NASH)
- Liver fibrosis
- Pulmonary fibrosis
- Kidney fibrosis
- Cardiac fibrosis
- Diabetic retinopathy
- Cancers with fibrotic components including myelofibrosis and pancreatic cancer
- Inflammatory bowel diseases
Pharmaxis aims to improve success rates, minimise drug discovery costs and speed up development timelines by focusing on targets that have been independently validated in diseases with limited treatment options and where its amine oxidase platform can be utilised.
Amine oxidase drug development programs currently being investigated by Pharmaxis include:
- Selective LOXL2 inhibitor for NASH, lung, liver and kidney fibrosis - successfully completed phase 1 trials in the fourth quarter of 2018
- LOX inhibitors for severe fibrotic indications including scaring and some cancers. The systemic LOX inhibitor is scheduled to commence a phase 2 study of myelofibrosis, a rare bone cancer with high unmet need in Q4 2020.
- SSAO combination inhibitors for inflammation (preclinical development)